van der Poel HG - Search Results

1

Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice.

van Rhijn BW, Catto JW, Goebell PJ, Knüchel R, Shariat SF, van der Poel HG, Sanchez-Carbayo M, Thalmann GN, Schmitz-Dräger BJ, Kiemeney LA. van Rhijn BW, et al. Among authors: van der poel hg. Urol Oncol. 2014 Oct;32(7):1078-87. doi: 10.1016/j.urolonc.2014.07.002. Epub 2014 Sep 10. Urol Oncol. 2014. PMID: 25217465 Review.

2

Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer.

van der Poel HG, Witjes JA, van Stratum P, Boon ME, Debruyne FM, Schalken JA. van der Poel HG, et al. Among authors: van stratum p. Urology. 1996 Sep;48(3):357-64. doi: 10.1016/S0090-4295(96)00210-5. Urology. 1996. PMID: 8804485 Free article. Clinical Trial.

3

Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer.

Vet JA, Witjes JA, Marras SA, Hessels D, van der Poel HG, Debruyne FM, Schalken JA. Vet JA, et al. Among authors: van der poel hg. Clin Cancer Res. 1996 Jun;2(6):1055-61. Clin Cancer Res. 1996. PMID: 9816267

4

Can histopathology predict treatment outcome following high-energy transurethral microwave thermotherapy of the prostate? Results of a biopsy study.

d'Ancona FC, Albers YH, Kiemeney LA, Xue Y, Smedts F, van der Poel HG, Debruyne FM, de la Rosette JJ. d'Ancona FC, et al. Among authors: van der poel hg. Prostate. 1999 Jun 15;40(1):28-36. doi: 10.1002/(sici)1097-0045(19990615)40:1<28::aid-pros4>3.0.co;2-u. Prostate. 1999. PMID: 10344721 Clinical Trial.

5

Bladder cancer in women.

van der Poel HG, Mungan NA, Witjes JA. van der Poel HG, et al. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(3):207-12. doi: 10.1007/s001920050046. Int Urogynecol J Pelvic Floor Dysfunct. 1999. PMID: 10430016 Review.

6

Markers for recurrence of superficial bladder cancer: what is valid?

van der Poel HG. van der Poel HG. Curr Opin Urol. 1999 Sep;9(5):401-6. doi: 10.1097/00042307-199909000-00006. Curr Opin Urol. 1999. PMID: 10579077 Review.

7

Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt.

van Rhijn BW, van der Poel HG, Boon ME, Debruyne FM, Schalken JA, Witjes JA. van Rhijn BW, et al. Among authors: van der poel hg. Urology. 2000 Mar;55(3):363-7. doi: 10.1016/s0090-4295(99)00460-4. Urology. 2000. PMID: 10699611

8

Gender differences in stage distribution of bladder cancer.

Mungan NA, Kiemeney LA, van Dijck JA, van der Poel HG, Witjes JA. Mungan NA, et al. Among authors: van dijck ja, van der poel hg. Urology. 2000 Mar;55(3):368-71. doi: 10.1016/s0090-4295(99)00481-1. Urology. 2000. PMID: 10699612

9

Consecutive quantitative cytology in bladder cancer.

van der Poel HG, van Rhijn BW, Peelen P, Debruyne FM, Boon ME, Schalken JA. van der Poel HG, et al. Among authors: van rhijn bw. Urology. 2000 Oct 1;56(4):584-8. doi: 10.1016/s0090-4295(00)00726-3. Urology. 2000. PMID: 11018610

10

Can biological markers replace cystoscopy? An update.

van der Poel HG, Debruyne FM. van der Poel HG, et al. Curr Opin Urol. 2001 Sep;11(5):503-9. doi: 10.1097/00042307-200109000-00009. Curr Opin Urol. 2001. PMID: 11493772 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

487 results

Search Page